Valuation: Pharmigene, Inc.

Market Cap 345M 10.75M 9.43M 8.7M 8.04M 15.24M 1.03B 15.55M 105M 40.65M 504M 40.35M 39.47M 1.75B P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 915M 28.48M 24.98M 23.06M 21.31M 40.39M 2.73B 41.2M 277M 108M 1.33B 107M 105M 4.63B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 week-2.29%
Current month-5.91%
1 month-20.00%
3 months-32.94%
6 months-32.28%
Current year-30.91%
1 week 6.5
Extreme 6.5
6.88
1 month 6.18
Extreme 6.18
8.47
Current year 6.18
Extreme 6.18
11.85
1 year 6.18
Extreme 6.18
14.1
3 years 6.18
Extreme 6.18
25.7
5 years 6.18
Extreme 6.18
25.7
10 years 6.18
Extreme 6.18
36
Manager TitleAgeSince
Chief Executive Officer 67 03/11/2019
Chief Operating Officer 49 03/11/2019
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 76 23/11/2020
Director/Board Member 49 03/11/2019
Chairman 67 -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.29%-42.52%-70.52% 10.74M
-0.07%-6.23%+111.14%+136.69% 4.48B
-3.17%-9.88%+71.72%+233.77% 3.33B
-0.95%-6.92%-30.75%-41.82% 1.96B
-1.61%+7.81%+141.81%-40.88% 1.94B
-2.68%-5.81%+43.12%+173.04% 1.46B
-3.58%-1.57%-9.16%+45.39% 881M
-2.70%-6.34%+108.70%-52.71% 873M
-8.72%-15.59%-5.65% - 488M
-1.61%-0.96%-36.68%-17.99% 487M
Average -2.51%-2.72%+35.17%+40.55% 1.59B
Weighted average by Cap. -1.91%-3.17%+67.93%+95.15%

Financials

2024 2025
Net sales 117M 3.63M 3.18M 2.94M 2.71M 5.15M 347M 5.25M 35.32M 13.72M 170M 13.62M 13.33M 590M 200M 6.22M 5.46M 5.04M 4.66M 8.83M 596M 9M 60.58M 23.54M 292M 23.37M 22.86M 1.01B
Net income -82.86M -2.58M -2.26M -2.09M -1.93M -3.66M -247M -3.73M -25.11M -9.76M -121M -9.69M -9.48M -420M -73M -2.27M -1.99M -1.84M -1.7M -3.22M -218M -3.29M -22.12M -8.6M -106M -8.53M -8.35M -370M
Net Debt 458M 14.25M 12.5M 11.54M 10.67M 20.22M 1.36B 20.62M 139M 53.91M 668M 53.53M 52.35M 2.32B 570M 17.73M 15.55M 14.36M 13.27M 25.15M 1.7B 25.65M 173M 67.07M 831M 66.59M 65.13M 2.88B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
08/07/26 NT$6.840 0.00% 16,142
07/07/26 NT$6.840 -0.15% 138,007
06/07/26 NT$6.850 +0.29% 63,018
03/07/26 NT$6.830 +0.44% 44,051
02/07/26 NT$6.800 -2.86% 129,559
  1. Stock Market
  2. Stocks
  3. 7595 Stock